Rapamycin vs Metformin: Comparing the Two Most-Discussed Longevity Drugs

Rapamycin

Rapamycin forms a complex with FKBP12 that directly inhibits mTOR complex 1 (mTORC1), a master nutrient sensor and growth regulator. mTOR inhibition mimics the cellular state of nutrient deprivation — triggering autophagy (cellular cleaning and recycling), reducing protein synthesis, and shifting cells away from growth toward maintenance and repair. mTOR hyperactivation is implicated in multiple age-related pathologies including cancer, neurodegeneration, and cardiovascular disease. Intermittent rapamycin dosing (weekly or biweekly) may preferentially inhibit mTORC1 while minimising blunting of mTORC2, which mediates insulin signalling.

Metformin

Metformin inhibits mitochondrial complex I, reducing ATP production and raising AMP:ATP ratio, which activates AMPK. AMPK is a metabolic master switch that suppresses anabolic processes (including mTOR — creating some overlap with rapamycin), enhances glucose uptake, stimulates mitochondrial biogenesis, and activates FOXO transcription factors involved in stress resistance. Metformin also has AMPK-independent effects including reduction of hepatic gluconeogenesis, anti-inflammatory signalling via NF-κB, and gut microbiome modulation.

Rapamycin

Rapamycin has the most reproducible and dramatic longevity data of any drug in rigorous animal models. In the NIA Interventions Testing Program (ITP), rapamycin extended median lifespan in both male and female mice by 9–14% even when treatment began at 20 months (equivalent to ~60 human years). This late-life efficacy is remarkable and unique. Subsequent ITP studies with higher doses and earlier initiation have shown even greater effects. Lifespan extension has been replicated in yeast, worms, flies, and multiple mouse strains.

Metformin

Metformin has shown lifespan extension in C. elegans and several invertebrate models, but mouse data are mixed. The ITP study found metformin extended lifespan in male mice only at low doses — higher doses were actually detrimental, and female mice showed no benefit. This inconsistency across the sexes and doses has tempered enthusiasm for metformin as a primary longevity drug in preclinical models, though its downstream effects on cancer incidence and metabolic disease remain compelling.

Rapamycin

No completed longevity-specific RCTs exist for rapamycin in humans. Evidence comes from: immunosuppression data in transplant patients (cautionary — chronic high-dose use causes significant side effects), a 2014 study finding that low-dose rapamycin analogues improved vaccine immune response in elderly subjects (Mannick et al.), and observational data from the growing community of longevity practitioners using intermittent low-dose rapamycin. The PEARL trial (ongoing) is evaluating rapamycin in healthy older adults. Human evidence is promising but thin.

Metformin

Metformin has decades of human data across millions of patients. The UKPDS (UK Prospective Diabetes Study) established cardiovascular benefits in diabetic patients. A landmark Bannister et al. study (2014) found metformin-treated diabetics outlived matched healthy non-diabetic controls. The TAME trial (targeting aging in non-diabetics) is the definitive ongoing human longevity trial. Metformin's human evidence base is incomparably larger than rapamycin's for longevity-adjacent outcomes.

Rapamycin

Rapamycin's primary risks stem from its immunosuppressive effects. At transplant doses, it causes increased infection susceptibility, impaired wound healing, hyperlipidaemia, mouth sores, and insulin resistance. The longevity community's argument is that intermittent low doses (e.g., 5–6 mg once weekly) provide mTOR inhibition benefits with substantially reduced immunosuppression — supported by pharmacokinetic modelling but not rigorously validated in long-term human trials. The risk of impaired vaccine responses and infection risk requires careful individual risk assessment. Not appropriate for immunocompromised individuals.

Metformin

Metformin's risk profile is far better characterised. GI side effects are common on initiation but manageable. Lactic acidosis risk is real but mainly relevant in renal impairment. Vitamin B12 depletion is clinically significant and requires supplementation. Importantly, several studies suggest metformin may blunt mitochondrial adaptations to aerobic exercise — a meaningful concern for longevity-focused users who prioritise fitness. This exercise-blunting effect appears more concerning at higher doses and with concurrent supplementation.

Rapamycin

Rapamycin is a schedule-controlled prescription drug (immunosuppressant) and is rarely prescribed off-label by conventional physicians. Access typically requires finding a longevity-focused physician, a functional medicine doctor, or specialised telehealth platforms. Blood level monitoring (trough rapamycin levels, lipid panel, complete blood count, HbA1c) is important to ensure therapeutic dosing and catch metabolic side effects. Cost ranges from $50–200/month depending on dose and source.

Metformin

Metformin is available by prescription in all major countries and is actively prescribed off-label for longevity by growing numbers of physicians, including via longevity telehealth platforms. Monitoring is straightforward: periodic kidney function tests (eGFR) and vitamin B12 levels annually. Cost is extremely low for generic metformin ($4–20/month). Extended-release formulations reduce GI side effects substantially.